Key facts
- This page summarizes Michael Berman's Form 4 filing for InspireMD, Inc. (NSPR).
- 5 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 16 May 2023, 16:15.
Michael Berman - 12 May 2023 Form 4 Insider Report for InspireMD, Inc. (NSPR)
- Reporting relationship
- Director
- Issuer ticker
- NSPR
- Reported as of
- 12 May 2023
- Net transaction value
- +$600,003
- SEC form
- 4
- Accepted by SEC
- 16 May 2023, 16:15:57 UTC
- Prior SEC filing
- 04 Apr 2023
- Next SEC filing
- 19 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Craig Shore, Attorney-in-Fact for Michael Berman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Berman filed Form 4 for InspireMD, Inc. (NSPR) on 16 May 2023.
Change
- Previous filing in this sequence was filed on 04 Apr 2023.
- Current net transaction value: +$600,003.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NSPR
transaction
Common Stock
Purchase
- Transaction value
- $200,001
- Shares
- +122,497
- Change %
- Price
- $1.63
- Shares after
- 122,497
- Date
- 12 May 2023
- Ownership
- See footnote
- Footnotes
- F1, F2, F3
NSPR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 42,827
- Date
- 12 May 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NSPR
transaction
Derivative
Series H Warrants to purchase Common Stock
Purchase
- Transaction value
- $100,001
- Shares
- +61,249
- Change %
- Price
- $1.63
- Shares after
- 61,249
- Date
- 12 May 2023
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 61,249
- Exercise price
- $1.38
- Footnotes
- F2, F3, F4, F5
NSPR
transaction
Derivative
Series I Warrants to purchase Common Stock
Purchase
- Transaction value
- $100,000
- Shares
- +61,248
- Change %
- Price
- $1.63
- Shares after
- 61,248
- Date
- 12 May 2023
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 61,248
- Exercise price
- $1.38
- Footnotes
- F2, F3, F6, F7
NSPR
transaction
Derivative
Series J Warrants to purchase Common Stock
Purchase
- Transaction value
- $100,001
- Shares
- +61,249
- Change %
- Price
- $1.63
- Shares after
- 61,249
- Date
- 12 May 2023
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 61,249
- Exercise price
- $1.38
- Footnotes
- F2, F3, F8, F9
NSPR
transaction
Derivative
Series K Warrants to purchase Common Stock
Purchase
- Transaction value
- $100,000
- Shares
- +61,248
- Change %
- Price
- $1.63
- Shares after
- 61,248
- Date
- 12 May 2023
- Ownership
- See footnote
- Underlying class
- Common Stock
- Underlying amount
- 61,248
- Exercise price
- $1.38
- Footnotes
- F2, F3, F10, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 11 footnotes
Footnote F1
The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").
Footnote F2
The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.
Footnote F3
These securities are held by the Michael Berman Revocable Trust.
Footnote F4
The aggregate number of warrants reported in this row consists of 61,249 Series H Warrants that were acquired in the Private Placement.
Footnote F5
The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.
Footnote F6
The aggregate number of warrants reported in this row consists of 61,248 Series I Warrants that were acquired in the Private Placement.
Footnote F7
The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).
Footnote F8
The aggregate number of warrants reported in this row consists of 61,249 Series J Warrants that were acquired in the Private Placement.
Footnote F9
The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.
Footnote F10
The aggregate number of warrants reported in this row consists of 61,249 Series K Warrants that were acquired in the Private Placement.
Footnote F11
The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.